Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

NCT00496431 is registered in ClinicalTrials.gov with Italfarmaco as lead sponsor.

NCT NCT00496431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00496431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Lead sponsor
Italfarmaco
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2007
Completion date
March 31, 2009
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's lymphoma